Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Summit Therapeutics

Summit Therapeutics, Cambridge, MA, USA
https://www.summittxinc.com/

SMT026738 (SMT-738)
FIRST-IN-CLASS ANTIBIOTIC

MDR Carbapenem-Resistant Enterobacteriaceae

Summit’s SMT-738 is the first of a novel class of antibiotics with a new mechanism of action that acts via the bacterial target, LolCDE. Combining a novel antibiotic class (SMT-738) with a clinically unexploited target (LolCDE) is thought to mitigate the risk of pre-existing resistance. The new drug could potentially allow for the effective treatment of Enterobacteriaceae-caused infections that currently have very limited treatment options due to resistance or toxicity of available treatments. CRE are a family of bacteria that has been dubbed “Nightmare Bacteria” by health officials because they cause deadly infections that are difficult or impossible to treat, and spread rapidly. They can cause bloodstream infections, urinary tract infections, and hospital-acquired pneumonias. Some strains of multidrug-resistant Enterobacteriaceae are resistant to all existing antibiotics. CRE bacteria are more likely to emerge in healthcare settings, and patients using devices such as catheters or recovering from surgery may be most vulnerable. SMT-738 was discovered using Summit’s proprietary technology, the Discuva Platform. The company expects to begin Phase 1 studies in 2023.

Current Development Stage: Preclinical

CARB-X Investment: Initial investment of up to $4.1m with potential option payments up to $3.7m.

Initial CARB-X Investment Date: January 1, 2021

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023